EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study

Amica K Ko, Laura Milana, Nicoletta Riva, Lorenza Bertu, Laurent Bertoletti, Jan Beyer-Westendorf, Marc Carrier, Aurelien Delluc, Elvira Grandone, Pieter Kamphuisen, Alejandro Lazo-Langner, Margherita Maffioli und 10 weitere

Journal of Thrombosis and Haemostasis · 2026-09 · 24 (9) · 3247-3255

DOI: 10.1016/j.jtha.2026.05.014 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-09. Verfasst von Amica K Ko und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Anticoagulants, Myeloproliferative Disorders, Splanchnic Circulation, Venous Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG, Pfizer Canada ULC, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Splanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism but relatively common in patients with myeloproliferative neoplasms (MPNs). Studies on management and outcomes for patients with MPN-SVT, including comparisons with non-MPN-SVT, are scarce. OBJECTIVES: We assessed anticoagulant management and recurrent thrombosis, bleeding, and survival outcomes in SVT patients with and without MPN. METHODS: We conducted a multicenter comparative cohort study in adults with SVT using individual patient data from 3 published studies and 2 hospital cohorts. Anticoagulant management after SVT diagnosis was evaluated; 6-month cumulative incidences of recurrent thrombosis, bleeding, and death were calculated. We used propensity score weighting to compare outcomes between patients with and without MPN. A subanalysis excluding patients with cirrhosis or solid cancer was performed. RESULTS: We investigated 1189 patients with SVT, 187 with underlying MPN. Anticoagulation was started in 76.1% of patients within 30 days after SVT diagnosis, 78.6% were still anticoagulated at 6 months; this was similar between patients with and without MPN. The 6-month cumulative incidence of recurrent thrombosis and bleeding was 2.5% and 4.5%, respectively. Overall survival was 93.7% at the 6-month follow-up. No significant differences were observed in clinical outcomes between patients with and without MPN, also confirmed by subanalyses. CONCLUSION: In this large cohort, incidences of recurrent thrombosis, bleeding and survival 6 months after SVT were similar in patients with and without MPN. This suggests that MPN-related SVT could be regarded similarly to noncirrhotic, nonmalignant SVT for anticoagulant management and outcomes. Prospective studies with long-term follow-up are still needed for MPN-related patients with SVT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsMyeloproliferative DisordersSplanchnic CirculationVenous ThrombosisAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedHemorrhageIncidenceRecurrenceRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

anticoagulantsbudd-chiari syndromehemorrhagemyeloproliferative disorderssplanchnic vein thrombosisvenous thrombosis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands; Hematology Unit, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.
  • Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.
  • Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • CHU de St-Etienne, Service de Medicine Vasculaire et Therapeutique, Saint-Etienne, France; INSERM, UMR1059, Universite Jean-Monnet, Saint-Etienne, France; INSERM, CIC-1408, CHU de Saint-Etienne, Saint-Etienne, France; I…
  • Department of Medicine I, Division Thrombosis Hemostasis, Dresden University Hospital, Dresden, Germany.

Förderung

  • Bayer AG
  • Pfizer Canada ULC
  • Canadian Institutes of Health Research
  • CanVECTOR
  • Santé

Zitieren

APA

Ko, A. K., Milana, L., Riva, N., Bertu, L., Bertoletti, L., Beyer-Westendorf, J., Carrier, M., Delluc, A., Grandone, E., Kamphuisen, P., Lazo-Langner, A., Maffioli, M., Poli, D., Schulman, S., Senzolo, M., Testa, S., Tosetto, A., Verhamme, P., Leebeek, F. W. G., …, & Lauw, M. N. (2026). Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study. Journal of Thrombosis and Haemostasis, 24(9), 3247-3255. https://doi.org/10.1016/j.jtha.2026.05.014

Vancouver

Ko AK, Milana L, Riva N, Bertu L, Bertoletti L, Beyer-Westendorf J, et al. Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study. Journal of Thrombosis and Haemostasis. 2026;24(9):3247-3255. doi:10.1016/j.jtha.2026.05.014

BibTeX
@article{Ko2026,
  author = {Ko, Amica K and Milana, Laura and Riva, Nicoletta and Bertu, Lorenza and Bertoletti, Laurent and Beyer-Westendorf, Jan and Carrier, Marc and Delluc, Aurelien and Grandone, Elvira and Kamphuisen, Pieter and Lazo-Langner, Alejandro and Maffioli, Margherita and Poli, Daniela and Schulman, Sam and Senzolo, Marco and Testa, Sophie and Tosetto, Alberto and Verhamme, Peter and Leebeek, Frank W G and Darwish Murad, Sarwa and Ageno, Walter and Lauw, Mandy N},
  title = {Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {9},
  pages = {3247--3255},
  doi = {10.1016/j.jtha.2026.05.014}
}
Kostenlos starten →